Faeth Therapeutics names Karen Vousden to board

• Faeth Therapeutics appointed Karen Vousden to its board, effective Sept. 11, 2026.
• Vousden has been a principal group leader at the Francis Crick Institute since 2017.
• Her prior roles include chief scientist at Cancer Research UK from 2016 to 2022.
• She has served on Bristol Myers Squibb’s board since 2018.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917128041) on September 17, 2026, and is solely responsible for the information contained therein.